Evercore ISI Increases Edwards Lifesciences (NYSE:EW) Price Target to $91.00

Edwards Lifesciences (NYSE:EW) had its target price raised by analysts at Evercore ISI from $89.00 to $91.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an “in-line” rating on the medical research company’s stock. Evercore ISI’s price target indicates a potential downside of 0.10% from the company’s previous close.

Several other analysts have also issued reports on EW. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Deutsche Bank Aktiengesellschaft upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $86.00 to $103.00 in a research note on Tuesday, May 14th. Barclays upped their target price on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 7th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Finally, Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $95.18.

Edwards Lifesciences Stock Down 0.2 %

Edwards Lifesciences stock opened at $91.09 on Tuesday. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. Edwards Lifesciences has a 12-month low of $60.57 and a 12-month high of $96.12. The firm’s fifty day moving average is $87.99 and its 200 day moving average is $85.56. The company has a market capitalization of $54.89 billion, a PE ratio of 39.26, a PEG ratio of 3.38 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, sell-side analysts predict that Edwards Lifesciences will post 2.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 857 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total value of $73,359.20. Following the sale, the vice president now owns 23,890 shares of the company’s stock, valued at $2,044,984. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,499 shares of company stock valued at $7,866,511. 1.27% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of large investors have recently made changes to their positions in EW. Beese Fulmer Investment Management Inc. grew its stake in shares of Edwards Lifesciences by 5.3% during the 2nd quarter. Beese Fulmer Investment Management Inc. now owns 147,924 shares of the medical research company’s stock valued at $13,664,000 after acquiring an additional 7,393 shares during the period. Massmutual Trust Co. FSB ADV grew its stake in shares of Edwards Lifesciences by 1.2% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 21,353 shares of the medical research company’s stock valued at $1,972,000 after acquiring an additional 261 shares during the period. GAMMA Investing LLC grew its stake in shares of Edwards Lifesciences by 30.5% during the 2nd quarter. GAMMA Investing LLC now owns 3,375 shares of the medical research company’s stock valued at $312,000 after acquiring an additional 788 shares during the period. Cullen Investment Group LTD. grew its stake in shares of Edwards Lifesciences by 1.0% during the 2nd quarter. Cullen Investment Group LTD. now owns 19,456 shares of the medical research company’s stock valued at $1,797,000 after acquiring an additional 197 shares during the period. Finally, Maxwell Wealth Strategies Inc. grew its stake in shares of Edwards Lifesciences by 481.8% during the 1st quarter. Maxwell Wealth Strategies Inc. now owns 20,811 shares of the medical research company’s stock valued at $1,829,000 after acquiring an additional 17,234 shares during the period. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.